Evidence map›Paper›PMID 26554585›Full record

ArticlePloS one2015

A Naturally Occurring rev1-vpu Fusion Gene Does Not Confer a Fitness Advantage to HIV-1.

Simon M Langer, Kristina Hopfensperger, Shilpa S Iyer, Edward F Kreider, Gerald H Learn, Lan-Hui Lee, Beatrice H Hahn, Daniel Sauter

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Unusual Fusion Proteins of HIV-1.Frontiers in microbiology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Simon M LangerInstitute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Kristina HopfenspergerInstitute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Shilpa S IyerDepartments of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States of America.
Edward F KreiderDepartments of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States of America.
Gerald H LearnDepartments of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States of America.
Lan-Hui LeeInstitute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Beatrice H HahnDepartments of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States of America.
Daniel SauterInstitute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Universität Ulm · DEUniversity of Pennsylvania · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protectionP01AI088564 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHAW, GEORGE M · 2010 to 2014
$12.7M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
Restriction of HIV-1 transmission by type 1 interferonsR01AI114266 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2018
$3.2M
Harnessing type 1 IFN-stimulated antiviral mechanisms for HIV vaccine designR01AI111789 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2017
$816k
Discovery of a Novel Immune Response to the 5' Leader of HIV-1F30AI112426 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KREIDER, EDWARD · 2014 to 2015
$76k
NIAID NIH HHS F30 AI112426NIAID NIH HHS F30 AI112426-01NIAID NIH HHS P01 AI 088564NIAID NIH HHS P01 AI088564NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI111789NIAID NIH HHS R01 AI 114266NIAID NIH HHS R01 AI114266NIAID NIH HHS T32 AI007632NIAID NIH HHS UM1 AI 100645NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

backgroundPandemic strains of HIV-1 (group M) encode a total of nine structural (gag, pol, env), regulatory (rev, tat) and accessory (vif, vpr, vpu, nef) genes. However, some subtype A and C viruses exhibit an unusual gene arrangement in which the first exon of rev (rev1) and the vpu gene are placed in the same open reading frame. Although this rev1-vpu gene fusion is present in a considerable fraction of HIV-1 strains, its functional significance is unknown.

resultsExamining infectious molecular clones (IMCs) of HIV-1 that encode the rev1-vpu polymorphism, we show that a fusion protein is expressed in infected cells. Due to the splicing pattern of viral mRNA, however, these same IMCs also express a regular Vpu protein, which is produced at much higher levels. To investigate the function of the fusion gene, we characterized isogenic IMC pairs differing only in their ability to express a Rev1-Vpu protein. Analysis in transfected HEK293T and infected CD4+ T cells showed that all of these viruses were equally active in known Vpu functions, such as down-modulation of CD4 or counteraction of tetherin. Furthermore, the polymorphism did not affect Vpu-mediated inhibition of NF-кB activation or Rev-dependent nuclear export of incompletely spliced viral mRNAs. There was also no evidence for enhanced replication of Rev1-Vpu expressing viruses in primary PBMCs or ex vivo infected human lymphoid tissues. Finally, the frequency of HIV-1 quasispecies members that encoded a rev1-vpu fusion gene did not change in HIV-1 infected individuals over time.

conclusionsExpression of a rev1-vpu fusion gene does not affect regular Rev and Vpu functions or alter HIV-1 replication in primary target cells. Since there is no evidence for increased replication fitness of rev1-vpu encoding viruses, this polymorphism likely emerged in the context of other mutations within and/or outside the rev1-vpu intergenic region, and may have a neutral phenotype.

Indexed as

Gene Expression Regulation, ViralGene FusionHEK293 CellsHIV-1Human Immunodeficiency Virus ProteinsHumansrev Gene Products, Human Immunodeficiency VirusRNA, ViralViral Regulatory and Accessory ProteinsViroporin ProteinsHuman Immunodeficiency Virus Proteinsrev Gene Products, Human Immunodeficiency VirusRNA, ViralViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1

Identifiers

PMID26554585
PMCPMC4640844
OpenAlexW2263958059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.